Hematology

In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.

In phase 1/2 BRUIN, most patients with CLL/SLL or MCL had stable or improved PROs during pirtobrutinib treatment.

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

Final phase 3 results assessed 5-year efficacy and safety of etranacogene dezaparvovec in adults with hemophilia B.

In a large global phase 3 trial, investigators evaluated whether adding the CD19-targeted monoclonal antibody tafasitamab to the established lenalidomide–rituximab regimen could improve outcomes for adults...

Recognizing the lack of actionable monitoring guidance in transthyretin amyloid cardiomyopathy, international experts recently reviewed published prognostic data and updated proposed criteria to help...

A pooled analysis of 4 MagnetisMM trials evaluated dosing strategies for elranatamab, a BCMA-CD3 bispecific antibody, to identify the optimal regimen that mitigates cytokine release syndrome in patients...

An open-label, randomized trial found that daratumumab and hyaluronidase-fihj administered subcutaneously improved the risk of disease progression or death in patients with multiple myeloma. As a result,...

A large, real-world comparative analysis evaluated 1-year clinical and safety outcomes among patients with chronic lymphocytic leukemia receiving venetoclax-based versus Bruton's tyrosine kinase...

A large real-world cohort study presented at 67th ASH Annual Meeting and Exposition examined whether adding low-dose aspirin to warfarin improves outcomes in patients with antiphospholipid syndrome and...